Future large-scale, multicenter, prospective interventional trials are needed to delineate the characteristics of patients who benefit from earlier initiation of RRT.
Accordingly, this hypothesis is currently under investigation through a multicenter prospective interventional study [ 33].
ESCAPED was a multicenter, prospective, interventional study, entitled "Early Thoracic CT-Scan for Community-Acquired Pneumonia at the Emergency Department ESCAPEDD)" [ 11], conducted from November 2011 to January 2013, in four emergency departments (EDs) of four tertiary teaching hospitals in Paris, France, designed to measure the impact of thoracic CT scan on clinical decision.
The REPOSE Study, a European, multicenter, prospective, non-interventional study, investigated the effectiveness and safety of real-life use of onabotulinumtoxinA for chronic migraine (CM).
The present multicenter, prospective, non-interventional study F1J-SB-B009 F1J-SB-B009 F1J-SB-B009uence of early changes investigatedpressed pathents on long-term changes influencesive symptofs during trearlynt with duloxetine in changesl practine over a PPSindepressednths.
ADDITIONS was a non-interventional, multicenter prospective study including 2,330 patients with stable angina.
Multicenter, prospective, 6-month, non-interventional study in adult outpatients with a depressive episode and starting treatment with duloxetine.
ACTION was the first international, non-interventional, multicenter, prospective cohort study to evaluate patient retention and effectiveness of abatacept treatment in patients with moderate-to-severe RA.
This global, multicenter, prospective, double-blind, non-interventional study aims to derive and validate cutoffs for the sFlt-1/PlGF ratio, to rule out (for 1 week) or rule in (within 4 weeks) the occurrence of preeclampsia/eclampsia/HELLP syndrome.
The present work was conducted with baseline data, relating to a Spanish sample in the European non-interventional, multicenter, prospective, observational INSTIGATE study, in which we provide a description of the profile of the DM2 patient who begins insulin treatment in primary and/or secondary care in Spain.
PROGNOSIS is a multicenter, prospective, double-blind, non-interventional study designed to derive (part 1) and to validate (part 2) an sFlt-1/PlGF ratio cutoff-based short-term prediction model for each of the two scenarios described in the primary objectives: To rule out preeclampsia/eclampsia/HELLP syndrome occurring within 1 week of assessment.
